ANI Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 642
- Market Cap
- $1.3B
- Introduction
ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.
Prucalopride Tablets for Chronic Idiopathic Constipation Launches, Approved for 180-Day
FDA approved prucalopride tablets for chronic idiopathic constipation, showing efficacy in increasing bowel movements. Studies confirm its safety and effectiveness, with common side effects being gastrointestinal disorders and headache.
FDA Approves Prucalopride Tablets, a Generic Version of Motegrity, with 180-Day CGT Exclusivity
ANI Pharmaceuticals received FDA approval for Prucalopride Tablets, a generic version of Motegrity, with 180-day CGT exclusivity. Studies highlight Prucalopride's role in treating chronic constipation, dysphagia, and its potential in preventing major depression. Research also explores its efficacy in various gastrointestinal disorders and its comparison with other treatments for constipation and opioid-induced constipation.
Related Clinical Trials:
ANI Pharmaceuticals launches Prucalopride Tablets after FDA approval
ANI Pharmaceuticals (ANIP) received FDA approval and launched Prucalopride Tablets, a generic version of Motegrity, with U.S. annual sales around $168.0M.
ANI Pharmaceuticals Launches First Generic Motegrity with Exclusive 180-Day Market Access
ANI Pharmaceuticals received FDA approval for Prucalopride Tablets, the first generic of Motegrity®, with 180-day CGT exclusivity, targeting a $168.0 million U.S. market.
ANI Pharmaceuticals Inc (ANIP) Launches Generic Prucalopride Tablets
ANI Pharmaceuticals launched Prucalopride Tablets, a generic of Motegrity®, with FDA approval and 180-day exclusivity, targeting a $168M U.S. market. This move highlights ANI's R&D strength and generics market position, despite regulatory and competition risks.
ANI Pharmaceuticals Launches Prucalopride Tablets Following FDA Approval
ANI Pharmaceuticals launched generic Prucalopride Tablets after FDA approval, gaining 180-day market exclusivity. Targeting a $168M U.S. market, this move showcases ANI's R&D strength in generics and rare diseases, aiming to improve patient lives.
Macular Edema Global Clinical Trials Review 2024
The 'Macular Edema - Global Clinical Trials Review, 2024' report by ResearchAndMarkets.com offers an overview of global clinical trials on Macular Edema, including trial numbers, enrollment, regions, countries, phases, statuses, and sponsor types. It highlights prominent drugs and companies involved, and provides enrollment trends and recent news.
Gastroparesis Drugs Market size to increase by USD 1.42 Billion between 2023 to 2028
The global gastroparesis drugs market is projected to grow by USD 1.42 billion from 2024 to 2028, with a CAGR of 3.69%. Key segments include drug class, disease type, and geography. Prokinetic drugs like metoclopramide and domperidone are significant for managing symptoms. New drugs under development aim to improve treatment outcomes.
Sustained Release Excipients Market Size, Share | CAGR Of 8.5%
The Global Sustained Release Excipients Market is projected to grow from US$ 1.4 billion in 2023 to US$ 3.2 billion by 2033, driven by increasing demand for controlled drug delivery systems. North America leads with a 42.4% share, while advancements in nanotechnology and personalized medicine are set to propel market growth.
© Copyright 2025. All Rights Reserved by MedPath